Immatics (IMTXW) Competitors $0.02 0.00 (-23.88%) Closing price 03/28/2025 09:29 AM EasternExtended Trading$0.02 0.00 (0.00%) As of 03/28/2025 09:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsShort InterestTrendsBuy This Stock IMTXW vs. ATNFW, LBPSW, AARD, AEHAW, AIMDW, ALVOW, ACABW, BFRIW, BTMDW, and BCTXWShould you be buying Immatics stock or one of its competitors? The main competitors of Immatics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aardvark Therapeutics (AARD), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), and BriaCell Therapeutics (BCTXW). These companies are all part of the "pharmaceutical products" industry. Immatics vs. 180 Life Sciences 4D pharma Aardvark Therapeutics Aesther Healthcare Acquisition Ainos Alvotech Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Immatics (NASDAQ:IMTXW) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability, media sentiment, risk and valuation. Which has preferable valuation & earnings, IMTXW or ATNFW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmatics$115.50MN/AN/AN/AN/A180 Life SciencesN/AN/AN/AN/AN/A Is IMTXW or ATNFW more profitable? Company Net Margins Return on Equity Return on Assets ImmaticsN/A N/A N/A 180 Life Sciences N/A N/A N/A Does the MarketBeat Community believe in IMTXW or ATNFW? Immatics and 180 Life Sciences both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformImmaticsN/AN/A180 Life SciencesN/AN/A Does the media refer more to IMTXW or ATNFW? In the previous week, Immatics and Immatics both had 1 articles in the media. Immatics' average media sentiment score of 1.89 equaled 180 Life Sciences'average media sentiment score. Company Overall Sentiment Immatics Very Positive 180 Life Sciences Very Positive SummaryImmatics beats 180 Life Sciences on 1 of the 1 factors compared between the two stocks. Remove Ads Get Immatics News Delivered to You Automatically Sign up to receive the latest news and ratings for IMTXW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMTXW vs. The Competition Export to ExcelMetricImmaticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$110.49M$5.63B$7.84BDividend YieldN/A3.78%5.33%4.01%P/E RatioN/A3.1423.6018.74Price / SalesN/A4,278.81388.2490.77Price / CashN/A12.7538.1734.64Price / BookN/A36.766.894.23Net IncomeN/A-$91.48M$3.20B$247.47M7 Day PerformanceN/A-2.37%-3.55%-3.56%1 Month PerformanceN/A59.30%1.52%-5.81%1 Year PerformanceN/A85.98%9.37%-0.96% Immatics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMTXWImmaticsN/A$0.02-23.9%N/A-99.4%$0.00$115.50M0.00260Positive NewsGap UpATNFW180 Life SciencesN/A$0.01+6.1%N/A-7.3%$0.00N/A0.007LBPSW4D pharmaN/AN/AN/AN/A$0.00$522,000.000.00N/AAARDAardvark TherapeuticsN/A$9.24-6.8%$30.50+230.1%N/A$0.00N/A0.0018Analyst ForecastQuiet Period ExpirationNews CoverageGap DownAEHAWAesther Healthcare AcquisitionN/A$0.02+0.5%N/A-92.1%$0.00N/A0.002AIMDWAinosN/A$0.11-34.3%N/A+86.5%$0.00$20,729.000.0040Gap DownALVOWAlvotechN/A$2.61-10.0%N/A-52.7%$0.00$391.87M0.004Short Interest ↓News CoveragePositive NewsGap UpACABWAtlantic Coastal Acquisition Corp. IIN/A$0.03flatN/AN/A$0.00N/A0.0015BFRIWBiofronteraN/A$0.09+66.9%N/AN/A$0.00$35.36M0.0070Positive NewsGap DownHigh Trading VolumeBTMDWbioteN/A$0.07flatN/A-88.1%$0.00$197.19M0.00N/ABCTXWBriaCell TherapeuticsN/A$0.09-17.9%N/A-93.1%$0.00N/A0.008Short Interest ↓News CoveragePositive NewsGap Down Remove Ads Related Companies and Tools Related Companies 180 Life Sciences Alternatives 4D pharma Alternatives Aardvark Therapeutics Alternatives Aesther Healthcare Acquisition Alternatives Ainos Alternatives Alvotech Alternatives Atlantic Coastal Acquisition Corp. II Alternatives Biofrontera Alternatives biote Alternatives BriaCell Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMTXW) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics Please log in to your account or sign up in order to add this asset to your watchlist. Share Immatics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
